CN102247418A - 竹节参总皂苷、竹节参多糖的保肝作用 - Google Patents
竹节参总皂苷、竹节参多糖的保肝作用 Download PDFInfo
- Publication number
- CN102247418A CN102247418A CN 201010176648 CN201010176648A CN102247418A CN 102247418 A CN102247418 A CN 102247418A CN 201010176648 CN201010176648 CN 201010176648 CN 201010176648 A CN201010176648 A CN 201010176648A CN 102247418 A CN102247418 A CN 102247418A
- Authority
- CN
- China
- Prior art keywords
- panax japonicus
- panacis japonici
- rhizoma panacis
- total saponins
- japonicus total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007949 saponins Chemical class 0.000 title claims abstract description 47
- 229930182490 saponin Natural products 0.000 title claims abstract description 44
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 42
- 241000168720 Panax japonicus Species 0.000 title claims abstract description 41
- 235000003174 Panax japonicus Nutrition 0.000 title claims abstract description 41
- 150000004676 glycans Chemical class 0.000 title claims abstract description 41
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 41
- 210000004185 liver Anatomy 0.000 title claims abstract description 12
- 239000001397 quillaja saponaria molina bark Substances 0.000 title abstract description 6
- 230000000694 effects Effects 0.000 title description 8
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- 235000017709 saponins Nutrition 0.000 claims description 41
- 231100000753 hepatic injury Toxicity 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 5
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 239000007788 liquid Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 13
- 239000011734 sodium Substances 0.000 description 12
- 238000005303 weighing Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 206010067125 Liver injury Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 6
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 6
- 229960002855 simvastatin Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000008802 xuezhikang Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
竹节参总皂苷、竹节参多糖及竹节参总皂苷和竹节参多糖组合物的保肝用途，可与药学上可接受载体混合。
Description
技术领域
本发明的涉及竹节参总皂苷、竹节参多糖的保肝用途。
背景技术
肝损伤主要包括暴力性肝损伤、病理性肝损伤、化学性肝损伤等。其中暴力性肝损伤多表现明显快速，且严重。而病理性肝损伤和化学性肝损伤最为常见。在化学性肝损伤中，酒精和药物造成的肝损伤最为普遍，已经成为严重威胁人民生命安全和生活质量的重要因素。现在化学药物对肝损伤的治疗多采用干扰素疗法，但存在用药剂量大，费用高，毒副作用大，停药后易复发等缺点。而中药对肝损伤的治疗多采取复方汤药，或脱胎于复方的中成药，其药味众多，导致质量难以控制。因此，急切需要开发出来源于单一植物，成分简单，疗效明确的有效部位或有效成分，用于急慢性肝损伤的治疗。
竹节参为五加科人参属多年生草本植物Panax japonicus C1 A1 Mey1的干燥根。原是一种名贵的民间中草药，现已收载于《中华人民共和国药典》，药用功能类似人参和三七。竹节参生于山坡沟边、阴湿地区或岩石沟涧旁。主要分布于贵州、湖南、云南、安徽、江西、湖北等地。每年秋季采挖，除去茎叶，分出肉质根，将根茎除去外皮，晒干或阴干即可入药。始载于《本草纲目拾遗》。竹节参甘、微苦，温。具有活血化瘀、消肿止痛、滋补强壮等多种功效。既有类似人参的滋补强壮作用，又有类似三七的散瘀止痛、止血、祛痰作用，主要用于病后虚弱，劳嗽咳血，咳嗽痰多，跌打损伤。竹节参含有多种皂苷、挥发油、糖类和多种氨基酸。
本发明要解决的技术问题是研究竹节参总皂苷、竹节参多糖的保肝用途。为解决上述问题，提供技术方案如下。
竹节参总皂苷、竹节参多糖在保肝上的应用。
所述保肝方面的运用包括对肝损伤的预防和治疗。
所述组合物包括竹节参总皂苷、竹节参多糖与药学上可接受的载体或者常规食用辅料。
本发明对四氯化碳造成的肝损伤动物模型具有的降低谷丙转氨酶和谷草转氨酶的显著性作用。本发明包括用竹节参总皂苷、竹节参多糖与药学上可接受载体混合。
药学上可接受的载体包括口服制剂辅料或胃肠外途径给药的辅料。给药途径可以是口服、注射、局部给药等。根据本发明的技术方案，该组合物可以是口服制剂或注射用制剂，其中口服制剂包括胶囊剂、软胶囊剂、颗粒剂、口服液、片剂、滴丸等。所用辅料包括：淀粉、蔗糖、乳糖、糖粉、葡萄糖、甘露醇、木糖醇、聚乙二醇、异丙醇、吐温-80、甘油、丙二醇、微晶纤维素钠、糊精、环糊精、氯化钠、维生素C、半胱氨酸、柠檬酸、硫代硫酸钠、亚硫酸钠、硬脂酸盐和明胶等常规辅料，制剂的后期制备工艺及设备均属制药领域的常规技术，本发明对此不作限定，故在此不予详述。
本发明组合物口服给药的剂量为2-3次/天，0.25～0.50g/次。
本发明竹节参总皂苷、竹节参多糖提取物是从天然的中药竹节参中提取得到的，竹节参是常用的中草药，有长期的中医用药经验，该药使用安全性高，无明显毒性作用记载。
竹节参总皂苷、竹节参多糖具有确切的降低模型动物谷丙转氨酶和谷草转氨酶的作用。因此，竹节参总皂苷、竹节参多糖有开发成保肝药物的前景。
实施例一竹节参总皂苷的提取、纯化和制备
取竹节参粗粉，加入10倍量的60％的乙醇，浸泡2小时，水浴回流提取2小时，滤过，得滤液。药渣再用10倍量的60％的乙醇回流提取2次，每次2小时，滤过。合并3次滤液，减压回收乙醇至无醇味，配制成药材∶药液(g/ml)为1∶1的溶液。上已经处理好的HPD-100大孔树脂柱，一次用水、60％的乙醇洗脱。合并60％的乙醇洗脱液，回收溶剂至近干，经65℃减压干燥，得到竹节参总皂苷。
实施例二竹节参多糖的提取、纯化和制备
取竹节参粗粉，加入10倍量的水，浸泡2小时，直火煎煮提取1.5小时，滤过，得滤液。药渣再用10倍量的水直火煎煮提取2次，每次1.5小时，滤过。合并3次滤液，减压浓缩至体积适量。加乙醇至浓度为70％进行醇沉，室温下放置12小时以上，滤过，收集沉淀物，反复醇沉2次，合并沉淀物，经65℃减压干燥，得到竹节参多糖。
实施例三竹节参总皂苷和竹节参多糖的保肝实验研究
1.实验材料
1.1药品试剂
联苯双酯片(江苏鹏鹞药业有限公司，批号0811161)；辛伐他汀片(上海信谊万象药业股份有限公司，批号：080201)；血脂康胶襄(北京北大维信生物科技有限公司，批号：20080708)；四氯化碳(
北京市新光化学试剂厂生产)；花生油(食用油，山东玉皇粮油食品有限公司生产)；谷丙转氨酶(ALT)临床诊断试剂盒(上海科欣生物技术研究所，批号20090401)；谷草转氨酶(AST)临床诊断试剂盒(上海科欣生物技术研究所，批号20090301)。竹节参多糖(D1)、竹节参总皂苷(Z1)为本实验室自制。
1.2实验仪器
721分光光度计(上海菁华仪器厂)，LXJ-II离心机(上海医用分析仪器厂)，Satrious电子天平(德国)；恒温水浴锅(上海亚荣生化仪器厂)；移液枪；，低温高速离心机(天美Z323K)。
1.3实验动物
昆明种雄性小白鼠，体重18～22g，由中国药科大学动物中心提供。
2.实验样品的制备
实施例一、二中制备的竹节参总皂苷和竹节参多糖。
3.试验样品液的配制
3.1.CMC-Na溶液的配制：精密称取5gCMC-Na，1000mL蒸馏水，配制成浓度为0.5％的CMC-Na溶液。
3.2.阳性对照药取联苯双酯液制备：取联苯双酯片16片(25mg/片)，置于研钵中碾成细粉，溶解于40ml水中，得10mg/ml的联苯双酯混悬液，为阳性对照药液。
3.3.阳性对照药血脂康药液的配制：精密称取5g内容物，以0.5％CMC-Na混悬，定容至100ml，配制成浓度为0.05g/ml的药液样品。
3.4.阳性对照药辛伐他汀药液的配制：精密称取14g辛伐他汀片(含辛伐他汀70mg)，100ml0.5％CMC-Na混悬，配成浓度为0.0007g/ml的药液样品。
3.5.高剂量竹节参多糖药液的配制：精密称取1.5g竹节参多糖。100ml 0.5％CMC-Na混悬，配制成浓度为0.015g/ml的药液样品。
3.6.低剂量竹节参多糖药液的配制：精密称取0.75g竹节参多糖，100ml0.5％CMC-Na混悬，配制成浓度为0.0075g/ml的药液样品。
3.7.高剂量竹节参总皂苷药液的配制：精密称取1.5g竹节参总皂苷。100ml 0.5％CMC-Na混悬，配制成浓度为0.015g/ml的药液样品。
3.8.低剂量竹节参总皂苷药液的配制：精密称取0.75g竹节参总皂苷，100ml0.5％CMC-Na混悬，配制成浓度为0.00715g/ml的药液样品。
3.9.高剂量竹节参总皂苷和多糖药液的配制：精密分别称取0.75g竹节参总皂苷和0.75g竹节参多糖。100ml 0.5％CMC-Na混悬，配制成浓度为0.015g/ml的药液样品。
3.10.低剂量竹节参总皂苷药液的配制：精密分别称取0.375g竹节参总皂苷和0.375g竹节参多糖。100ml0.5％CMC-Na混悬，配制成浓度为0.0075g/ml的药液样品。
4.实验方法
昆明种小鼠132只，18-22g，雌雄各半，随机分成11组，每组12只。分为正常空白对照组、高脂模型组、取联苯双酯阳性对照组、辛伐他汀阳性对照组、血脂康阳性对照组、竹节参总皂苷高剂量组、竹节参总皂苷低剂量组、竹节参多糖高剂量组、竹节参多糖低剂量组、竹节参多糖和竹节参总皂苷低剂量组、竹节参多糖和竹节参总皂苷高剂量组。灌胃给药。正常对照组和高脂模型组每日按0.2ml/10g灌胃0.5％CMCNa，给药组每日灌胃给予0.2ml/10g体积的相应药物，给药剂量分别为：取联苯双酯对照组0.2g/kg、血脂康对照组为1g/kg、辛伐他汀对照组为0.014g/kg、竹节参多糖高剂量组为0.3g/kg、竹节参多糖低剂量组为0.15g/kg、竹节参总皂苷高剂量组为0.3g/kg、竹节参总皂苷低剂量组为0.15g/kg、竹节参多糖和竹节参总皂苷高剂量组为0.15g多糖/kg和0.15g皂苷/kg、竹节参多糖和竹节参总皂苷低剂量组为0.075g多糖/kg和0.075g皂苷/kg。共给药6天。最后1次给药2小时后，除空白组外，其余8组均腹腔注射0.1％的四氯化碳花生油溶液0.1mL/10g。禁食16个小时后，于小鼠眼底静脉丛采血约0.5ml，分离血清(4000rp/min，10min，4℃)，利用试剂盒测定ALT、AST活力。
5.结果与讨论
表1.竹节参多糖(D1)、总皂苷(Z1)对小鼠血清谷丙转氨酶(ALT)的影响(n＝10，
)
注：▲表示模型与空白相比有显著性差异P＜0.05，▲▲表示模型与空白相比有极显著性差异P＜0.01。*表示各给药组与模型组相比有显著性差异P＜0.05，**表示各给药组与模型组相比有极显著性差异P＜0.01。下同。
表2.竹节参多糖(D1)、总皂苷(Z1)对小鼠血清谷草转氨酶(AST)的影响(n＝10，)
由表1和表2可知，竹节参多糖(D1)、总皂苷(Z1)及二者组合物(Z1D1)给药组与模型组相比，对CCl4致急性肝损伤模型小鼠的ALT、AST升高有极其显著性的降低作用，分别是P＜0.01和P＜0.05。实验显示竹节参多糖(D1)、总皂苷(Z1)及二者组合物(Z1D1)具有良好的保肝降酶作用。
Claims (4)
1.竹节参总皂苷、竹节参多糖及竹节参总皂苷和竹节参多糖组合物的保肝用途。
2.权利要求1中所述的保肝用途主要是通过对降低降低谷丙转氨酶和谷草转氨酶达到的。
3.权利要求1中所述的保肝用途可以被用在对肝损伤的预防和治疗。
4.权利要求1中所述的保肝用途，其最终实施形式包括竹节参总皂苷、竹节参多糖及竹节参总皂苷和竹节参多糖组合物与药学上可接受的载体或者常规食用辅料。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010176648 CN102247418B (zh) | 2010-05-19 | 2010-05-19 | 竹节参总皂苷、竹节参多糖的保肝作用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010176648 CN102247418B (zh) | 2010-05-19 | 2010-05-19 | 竹节参总皂苷、竹节参多糖的保肝作用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102247418A true CN102247418A (zh) | 2011-11-23 |
| CN102247418B CN102247418B (zh) | 2013-06-05 |
Family
ID=44975223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010176648 Active CN102247418B (zh) | 2010-05-19 | 2010-05-19 | 竹节参总皂苷、竹节参多糖的保肝作用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102247418B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104490965A (zh) * | 2014-12-03 | 2015-04-08 | 中南民族大学 | 竹节参多糖、竹节参总皂苷及竹节参皂苷v的应用 |
| CN105998118A (zh) * | 2016-07-05 | 2016-10-12 | 三峡大学 | 竹节参总皂苷在制备预防及治疗肝脏衰老的药物上的应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105963333A (zh) * | 2016-07-08 | 2016-09-28 | 重庆医药高等专科学校 | 竹节参总皂苷在制备抗溃疡性结肠炎药物中的应用 |
-
2010
- 2010-05-19 CN CN 201010176648 patent/CN102247418B/zh active Active
Non-Patent Citations (2)
| Title |
|---|
| 《国外医药的·植物药分册》 20011231 Nguyen T D 《人参属植物Panax vietnamensis防止CCl_4引起的小鼠肝毒性而不影响CYP2E1基因的表达》 第16卷, 第5期 * |
| 19961231 李翔，等 竹节参对四氯化碳诱发大鼠肝损伤模型保护作用的初步观察 8 第13卷, 第2期 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104490965A (zh) * | 2014-12-03 | 2015-04-08 | 中南民族大学 | 竹节参多糖、竹节参总皂苷及竹节参皂苷v的应用 |
| CN104490965B (zh) * | 2014-12-03 | 2017-08-18 | 中南民族大学 | 竹节参多糖、竹节参总皂苷及竹节参皂苷v的应用 |
| CN105998118A (zh) * | 2016-07-05 | 2016-10-12 | 三峡大学 | 竹节参总皂苷在制备预防及治疗肝脏衰老的药物上的应用 |
| CN105998118B (zh) * | 2016-07-05 | 2019-12-03 | 三峡大学 | 竹节参总皂苷在制备预防及治疗肝脏衰老的药物上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102247418B (zh) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102058632A (zh) | 一种药物组合物在制备防治酒精性肝损伤、脂肪肝及降血脂的药物中的应用 | |
| CN101342229A (zh) | 一种鸡骨草提取物的组合物、其制备方法和药物用途 | |
| CN103156869A (zh) | 从桑属植物提取的桑根酮c、桑根酮d及组合物的医药新用途 | |
| CN102247391B (zh) | 竹节参皂苷v的降血脂作用 | |
| CN102247418B (zh) | 竹节参总皂苷、竹节参多糖的保肝作用 | |
| CN101628021A (zh) | 柴胡有效部位的制备方法及其用途 | |
| CN102134268A (zh) | 竹节参皂苷Ⅳa制备方法以及在制备保肝降酶药物中的应用 | |
| CN104840527A (zh) | 一种含远志糖酯和人参皂苷的组合物及用途 | |
| WO2013155995A1 (zh) | 一种调节血脂的红曲葛根药物组合及其制备方法 | |
| CN103156997B (zh) | 一种治疗慢性肝病的中药有效部位组合物及其制备方法和应用 | |
| CN101007044B (zh) | 一种治疗溃疡病的药物组合物及其制备方法和用途 | |
| CN101890063B (zh) | 一种中药降血糖药及其制备方法 | |
| CN102247416B (zh) | 竹节参总皂苷的降血脂作用 | |
| CN102247400B (zh) | 竹节参多糖的降血脂作用 | |
| CN103385931B (zh) | 一种降血糖的药物组合物 | |
| CN107412462B (zh) | 一种黄龙咳喘胶囊的制备方法 | |
| CN102247417B (zh) | 竹节参总皂苷、竹节参多糖的减肥作用 | |
| CN104804056A (zh) | 楮头红提取物及其应用 | |
| CN109674848A (zh) | 一种甘草提取物的制备方法与用途 | |
| CN100569234C (zh) | 具有神经保护作用的银杏总内酯组合物 | |
| CN103006781A (zh) | 一种具有保肝作用的傣药复合提取物及其制备方法 | |
| CN102755450A (zh) | 一种消炎解毒中药组合物的制备方法 | |
| CN103211828B (zh) | 竹节参皂苷ⅳ在制备降血脂药物中的应用 | |
| CN101940614A (zh) | 胡桃楸乙酸乙酯部位在制备α-葡萄糖苷酶抑制剂的药物中的应用 | |
| CN101926848B (zh) | 一种治疗心脑血管病的药物组合物及其制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |